Combination Immunotherapy With Interferon-gamma and Nivolumab for Patients With Advanced Solid Tumors: A Phase 1 Study

Trial Profile

Combination Immunotherapy With Interferon-gamma and Nivolumab for Patients With Advanced Solid Tumors: A Phase 1 Study

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Feb 2018

At a glance

  • Drugs Interferon gamma (Primary) ; Nivolumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Feb 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2021.
    • 06 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2019.
    • 27 Feb 2017 According to a Horizon Pharma media release, safety data from the first two cohorts of this trial is presented at the American Society for Clinical Oncology - Society for Immunotherapy of Cancer meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top